Obinutuzumab is a monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, a type of cancer that affects the lymphatic system. It is given intravenously (into a vein) to patients who have not responded to previous treatments or who have become resistant to those treatments. Obinutuzumab works by binding to a protein known as CD20, which is found on the surface of cancerous B cells. By binding to this protein, obinutuzumab can help to destroy the cancerous B cells and reduce the size of the tumor. It is also used in combination with other medications to treat chronic lymphocytic leukemia.
Obinutuzumab, also commercially known as Gazyva, is a prescription medication classified as a monoclonal antibody. It targets specific types of blood cancers. Here's a breakdown of its key characteristics:
Function:
- Targets cancer cells: Obinutuzumab acts by attaching to a protein (CD20) present on the surface of certain cancerous B-cells. These B-cells are involved in some types of blood cancers.
- Triggers immune response: Once attached, Obinutuzumab essentially flags the cancerous cells for destruction. This alerts the body's immune system to recognize and attack these marked cells.
Applications:
- Chronic lymphocytic leukemia (CLL): Obinutuzumab is primarily used in combination with other chemotherapy drugs to treat CLL, a cancer affecting the white blood cells.
- Follicular lymphoma: This medication is also indicated for treating a specific type of non-Hodgkin lymphoma known as follicular lymphoma.
Important Considerations:
- Prescription medication: Obinutuzumab is a powerful drug and should only be administered under the strict supervision of a qualified oncologist (cancer specialist) in a healthcare setting.
- Combination therapy: Obinutuzumab is seldom used alone. It's typically combined with other chemotherapy drugs to achieve a more comprehensive therapeutic effect.
- Potential side effects: Like any medication, Obinutuzumab can cause various side effects, including:
- Infusion reactions (fever, chills, nausea)
- Increased risk of infections due to suppressed immune system
- Low blood cell counts
- Tumor lysis syndrome (rapid breakdown of cancer cells)